HY-133 is under clinical development by HyPharm and currently in Phase I for Staphylococcal Infections. According to GlobalData, Phase I drugs for Staphylococcal Infections have a 63% phase transition ...

P-128 is under clinical development by GangaGen Biotechnologies and currently in Phase II for Staphylococcus aureus Infections.

Department of Chemistry, Indiana University, 800 E. Kirkwood Avenue, Bloomington, Indiana 47405, United States ...

Some tissue matrices are fibrous, contained in protective cell walls, or behind tough peptidoglycan layers that are difficult to disassociate quickly and consistently, whiles others can easily be ...

Department of Biological and Environmental Science, Nanoscience Center, University of Jyvaskyla, P.O. Box 35, FI-40014 Jyvaskyla, Finland Institute of Biotechnology, Helsinki Institute of Life Science ...